Gemina Laboratories Ltd. announced the appointment of Dr. Bola Grace to the Board of Directors. Dr. Grace brings extensive leadership experience in the biotech/healthcare industry to the Board, having provided strategic, commercial and technical direction on many complex programmes, delivering numerous diagnostic products to the consumer marketplace. With a career that started in research and development at Unipath, she went on to hold a Lead Scientist role at Alere before becoming Head of R&D for the global leader in reproductive health testing, Swiss Precision Diagnostics (SPD), a company jointly owned by Abbott Laboratories and Proctor and Gamble.

Dr. Grace is a passionate believer in inclusive, user-centric design, not least because of its impact on healthcare equity. She holds a prestigious visiting professorship in this field with the UK's Royal Academy of Engineering. Dr. Grace has always succeeded in balancing her private sector career with her academic interests.

Beyond her current visiting professorship with the Royal Academy of Engineering, she previously held a 3-year visiting faculty position at Kings College London and a 9-year engagement with University College London (UCL), initially with the Elizabeth Garrett Anderson Institute for Women's Health, which became a visiting faculty position with UCL's Global Business School for Health. She has Bachelor and Master's degrees in biomedical sciences and molecular biology, and a Ph.D from UCL in population health and epidemiology. She also holds an executive MBA from Cambridge University.

She is a fellow of the Royal Society of Public Health and a Fellow of the Chartered Management Institute. With Dr. Grace's appointment to the Board, the Company also announced that Dr. James Tansey has resigned his directorship of Gemina. James will continue to serve the Company as an advisor.